Research
Hormonal
GLP-1 receptor agonists (specifically Liraglutide 3.0mg and Semaglutide 2.4mg) significantly reduce the incidence of type 2 diabetes in obese individuals with prediabetes, often outperforming placebo and sometimes matching or exceeding lifestyle interventions.
If you are obese and have prediabetes, ask your doctor about GLP-1 medications like Semaglutide or Liraglutide. They are highly effective at preventing diabetes, often working better than diet and exercise alone because they help control appetite and blood sugar automatically.
GoodSupportsHIGH confidence
In the liraglutide group 26 individuals (2%) of 1472 were diagnosed with T2DM vs 46 (6%) of 738 in the placebo group... semaglutide 2.4 mg could reduce the 10-year risk of progression to T2DM by 61%... (vs 13% reduction in the placebo group)
Why this rating
Based on large RCTs (SCALE, STEP 1/4) with significant risk reduction metrics.
Source
Pharmacological approaches to the prevention of type 2 diabetes mellitus
Priyanka Majety et al. · Frontiers in Endocrinology · 2023
DOI 10.3389/fendo.2023.1118848
narrative_reviewCited 86×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Metformin (850mg twice daily) reduces the incidence of type 2 diabetes by 31% in adults with prediabetes compared to placebo, with effects persisting for up to 22 years.Good
- Thiazolidinediones (specifically Pioglitazone) reduce the incidence of type 2 diabetes in individuals with impaired glucose tolerance, but their use is limited by adverse effects such as weight gain, fluid retention, and increased fracture risk.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →